Back to top
more

Exagen (XGN)

(Delayed Data from NSDQ)

$1.40 USD

1.40
3,840

-0.04 (-2.47%)

Updated Apr 17, 2024 03:49 PM ET

After-Market: $1.43 +0.03 (2.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (97 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.39% and 20.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of 150% and 3.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zynex Inc. (ZYXI) Q4 Earnings and Revenues Miss Estimates

Zynex Inc. (ZYXI) delivered earnings and revenue surprises of -76.47% and 12.44%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Despite Fast-paced Momentum, Exagen Inc. (XGN) Is Still a Bargain Stock

Exagen Inc. (XGN) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 41.67% and 28.92%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 15.38% and 18.21%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Veru Inc. (VERU) Reports Q2 Loss, Tops Revenue Estimates

Veru Inc. (VERU) delivered earnings and revenue surprises of -33.33% and 66.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 55.56% and 11.77%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 18.31% and 48.70%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

High Tide Inc. (HITI) Reports Q1 Loss, Tops Revenue Estimates

High Tide Inc. (HITI) delivered earnings and revenue surprises of 28.57% and 6.13%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 38.16% and 61.24%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Warby Parker Inc. (WRBY) Q3 Earnings Match Estimates

Warby Parker Inc. (WRBY) delivered earnings and revenue surprises of 0% and 2.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Quanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 4.76% and 18.11%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Lags Revenue Estimates

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 14.86% and 29.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q2 Loss, Lags Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of -41.82% and 25.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of -1.69% and 2.91%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AdaptHealth Corp. (AHCO) Reports Q1 Loss, Tops Revenue Estimates

AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -109.52% and 9.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates

Myomo, Inc. (MYO) delivered earnings and revenue surprises of -6.12% and 34.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Lags Q4 Earnings and Revenue Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -2.30% and 10.57%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q4 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (XGN) Reports Q3 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 2.33% and 0.97%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Exagen Inc. (XGN) Q3 Earnings Expected to Decline

Exagen Inc. (XGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exagen Inc. (XGN) Reports Q2 Loss, Tops Revenue Estimates

Exagen Inc. (XGN) delivered earnings and revenue surprises of 24.00% and 9.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?